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Inherited thrombocytopenias are a heterogeneous group of disorderscharacterized by abnormally low platelet counts which can be asso-ciated with abnormal bleeding. Next-generation sequencing has pre-
viously been employed in these disorders for the confirmation of sus-
pected genetic abnormalities, and more recently in the discovery of
novel disease-causing genes. However its full potential has not yet been
exploited. Over the past 6 years we have sequenced the exomes from
55 patients, including 37 index cases and 18 additional family members,
all of whom were recruited to the UK Genotyping and Phenotyping of
Platelets study. All patients had inherited or sustained thrombocytope-
nia of unknown etiology with platelet counts varying from 11x109/L to
186x109/L. Of the 51 patients phenotypically tested, 37 (73%), had an
additional secondary qualitative platelet defect. Using whole exome
sequencing analysis we have identified “pathogenic” or “likely patho-
genic” variants in 46% (17/37) of our index patients with thrombocy-
topenia.  In addition, we report variants of uncertain significance in 12
index cases, including novel candidate genetic variants in previously
unreported genes in four index cases. These results demonstrate that
whole exome sequencing is an efficient method for elucidating potential
pathogenic genetic variants in inherited thrombocytopenia. Whole
exome sequencing also has the added benefit of discovering potentially
pathogenic genetic variants for further study in novel genes not previ-
ously implicated in inherited thrombocytopenia. 
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ABSTRACT
Introduction
Inherited thrombocytopenias (IT) are a heterogeneous
group of disorders characterized by platelet counts of
less than 150x109/L in whole blood. Platelet counts are
considered normal when maintained at levels between
150x109/L and 450x109/L. This is achieved by homeosta-
tic processes controlling platelet production (throm-
bopoiesis), platelet senescence and platelet consump-
tion/destruction. Pathogenic mutations can result in a
disruption of these balanced processes causing IT.
However, the clinical manifestations are often dependent
on both a decreased platelet count and a qualitative or
acquired platelet defect and can vary dramatically from
severe and potentially life-threatening bleeding to no
symptoms. This variation is noted among individuals
shown to have the same underlying genetic causes of dis-
ease, suggesting that bleeding risk and phenotype are
complex traits.1
The average incidence of IT is estimated to be approx-
imately 270 cases per 1x106 live births.2 To date there are
27 individual IT disorders with known causative muta-
tions registered within the Online Mendelian Inheritance
in Man (OMIM) catalog, although 33 disease-causing
genes have been described.3
Genetic studies have played a major role in the diagno-
sis and progressive understanding of IT. The genes impli-
cated in the disease encode proteins that vary widely in
function and include transcription factors (ETV6, FLI1,
GATA1, GFI1B and RUNX1) and proteins involved in
cytoskeleton rearrangement and organization (ACTN1,
FLNA, GP1BA, GP1BB, GP9, TUBB1 and WAS).
However, some protein functions currently remain
unknown (SLFN14 and GNE).4-9. Although our knowl-
edge of the causes of IT continues to grow, presently a
genetic diagnosis is only reported in approximately 50%
of individuals.10-12
So far, genetic investigation into IT has focused on can-
didate gene sequencing and individual cases of whole
exome sequencing (WES) when a causative gene is not
obvious.9 With 50% of patients currently undiagnosed, a
change in the way we approach genetic diagnosis is nec-
essary. Here we present the first, large-scale, WES-only
approach to patients with suspected IT. We demonstrate
its application in determining possible genetic origins of
IT including identification of variants in novel candidate
causative genes. We combine this with an approach
implemented by the Genotyping and Phenotyping of
Platelets (GAPP) study, which combines WES analysis
with extensive platelet phenotyping to create a complete
method of diagnosis and gene discovery in this subset of
patients.
Methods
Study approval
The UK-GAPP study was approved by the National Research
Ethics Service Committee of West Midlands–Edgbaston (REC
reference: 06/MRE07/36) and participants gave written informed
consent in accordance with the Declaration of Helsinki. This
study was registered at www.isrctn.org as #ISRCTN 77951167.
The GAPP study is included in the National Institute of Health
Research Non-Malignant Haematology study portfolio
(ID9858).
Platelet counts, morphology and white blood 
cell counts
Results from patients’ samples were compared to ranges for
healthy volunteers for the specific method of morphology used.
Platelet counts for light transmission aggregometry and flow
cytometry analysis as well as mean platelet volume in platelet-rich
plasma were originally measured using the Beckman Coulter
counter (n=44). Subsequently, platelet counts, morphology and
white blood cell counts in whole blood were determined using the
Sysmex XN-1000 (n=11). The PLT-F channel was used to measure
platelet counts in whole blood and the immature platelet fraction.
Mean platelet volume was determined from the impedance PLT-I
channel. White blood cell counts were obtained using the Sysmex
XN-DIFF channel. All samples were tested against a normal range
which was established by measuring the counts for 40 healthy
individuals using the Sysmex XN-1000.
Platelet preparation and platelet function testing
Platelet function was assessed by light transmission aggregom-
etry, including lumiaggregometry, for samples with platelet counts
in platelet-rich plasma of >1x108/mL (n=13). An in-house flow-
cytometry assay was developed to assess platelet function in
patients with platelet counts in platelet-rich plasma <1x108/mL
(n=22). Platelets from individuals with borderline platelet counts in
platelet-rich plasma, between 1.0 and 1.5x108/mL, were assessed
using both assays (n=16).
Aggregometry was performed as previously described.13,14 For
flow cytometry, resting surface levels of CD42b, CD41 and GPVI
were assessed. The platelet-rich plasma was then stimulated with
ADP (3 and 30 µM), CRP (0.3 and 3 µg/mL) and PAR-1 peptide (10
and 100 µM). Membrane expression of P-selectin (FITC-conjugat-
ed mouse anti-human CD62P antibody, BD Pharmingen), a mark-
er of platelet alpha granule release, as well as fluorescent fibrino-
gen binding (a marker of integrin activation) was assessed by flow
cytometry on an Accuri C6 flow cytometer. Incubation took place
at 37ºC for 2 min and was terminated by adding a 5-fold excess of
ice-cold phosphate-buffered saline.
Whole exome sequencing
WES and bioinformatics analysis were performed as described
previously8,15,16 (Figure 1). 
The pathogenicity of variants was determined and called using
the consensus guidelines as set out by the American College of
Medical Genetics and Genomics and the Association for
Molecular Pathology (ACMG guidelines).17 Segregation was deter-
mined by Sanger sequencing of candidate variants in both affected
and unaffected family members, when available, and the classifi-
cation was adapted appropriately for the specific study and small
sample size.
Sanger sequencing
To verify candidate mutations and examine their segregation
among family members Sanger sequencing was performed using
standard methods on an ABI 3730 automated sequencer, as
described previously.8
Results
Recruitment of patients
To date, 55 patients with a suspected IT or sustained
reduced platelet counts have been enrolled from 25 UK
Haemophilia Care Centres and investigated as part of the
GAPP study. Before enrollment in the study, all patients
underwent clinical and genetic work-up to exclude known
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platelet disorders (including Bernard-Soulier syndrome
and MYH9-related disorders, analyzed initially by blood
film), idiopathic thrombocytopenic purpura and other
non-platelet disorders including von Willebrand disease
and inherited coagulation factor deficiencies. The patients’
bleeding phenotypes are displayed in Table 1. WES was
performed on genomic DNA from all patients, including
37 index cases, all of whom met the study’s entry criteria.
All patients, excluding F35.I and F35.II, were of white
British or mixed British ethnicity. All results following
platelet function testing and WES were reported back to
the referring hematology consultants to aid in genetic
counselling and disease management.
Platelet counts, morphology and function testing
Patients were recruited with a platelet count in whole
blood, at the time of enrollment, of less than 150x109/L.
Patients with platelet counts in the range of 150x109/L to
200x109/L remained enrolled in the study if they showed
a similar phenotype to related affected family members
and a platelet count below 150x109/L had been observed
prior to enrollment (patients F4.II, F11.III, F13.I and F30.II).
Platelet counts, mean platelet volume and immature
platelet fraction are displayed in Table 1. Of the 55 recruit-
ed patients, 12 were deemed to have a macrothrombocy-
topenia and three a microthrombocytopenia (Table 1).
White cell counts were within the normal range
(3.78x109/L - 10.11x109/L, n=40) in all patients analyzed
(n=11).
Platelet function studies revealed the presence of a sec-
ondary qualitative defect in addition to the low platelet
count in 37/51 (73%) of the 55 patients whose DNA
underwent WES and who were also available for platelet
function testing (Table 1). Of the 37 patients with a sec-
ondary qualitative defect, 89% (33/37) displayed defects
in both alpha and dense granule secretion. Five of these
patients with an observed granule secretion defect were
also suspected to have an additional Gi defect because of
reduced responses to all concentrations of ADP. The
remaining four patients without an observable granule
secretion defect showed abnormalities in alternative path-
ways (integrin activation, cyclooxygenase pathway and
GPVI surface levels) in addition to low platelet counts
(Table 1).
Whole exome sequencing
WES was performed on genomic DNA from all 55
patients, including 37 index cases, following platelet func-
tion testing. An average fold-coverage of 111 was
observed across all DNA samples analyzed by WES with
B. Johnson et al.
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Figure 1. Bioinformatics pipeline analysis of whole exome sequencing data.
Initial WES analysis focused on comparison with a panel of 358 genes (Online
Supplementary Table S1), after which screening of exome variants focused on
novel variants. Variants were classified using the ACMG consensus guidelines.
an average of 91% of target sequences having >20x cover-
age. Areas of poor coverage were analyzed manually
when occurring in previously IT-associated genes.
WES revealed between 24,000 and 25,000 variants (sin-
gle nucleotide variants, small scale insertions/deletions,
and splice site variations) in the DNA from each patient,
with an average of 197 novel variants per exome. On aver-
age, per individual, 2401 variants with a mean allele fre-
quency of <0.01 were observed, excluding synonymous
variants. By evaluating the specificity of the pipeline in
calling small variations, it was found that the sensitivity
was over 99% and the false discovery rate was approxi-
mately 3%. The percentage of the genes with ≤20x cover-
age for a panel of 358 platelet-related genes is included
within Online Supplementary Table S1. 
Copy number variations were detected using
ExomeDepth.18 The analysis revealed an average of 137
copy number variations per exome (n=32). No copy num-
ber variations were deemed potential candidates either
because of a high allele frequency or a lack of expression
or functional role of the gene within the
megakaryocyte/platelet lineage.   
Variants in known thrombocytopenia-causing genes
WES and downstream analysis identified variants with-
in 33 known IT-causing genes in 25 index cases (68%). All
variants exceeded 30x sequence coverage at the point of
variation and have been confirmed by Sanger sequencing.
Variants were selected from positive hits to genes within
the panel of 358 IT-associated genes (Online Supplementary
Table S1). On average, 37 variants per individual (range,
11-52) were noted in genes from the panel of 358 IT-asso-
ciated genes, of which on average four (range, 0-7) vari-
ants were significant per exome analyzed. 
In total 28 variants were noted in 14 genes previously
known to cause IT (Table 2). Twenty-one index cases pos-
sessed a single variant in a gene previously known to
cause IT. Four index cases possessed two variants in genes
previously known to cause IT. One variant, RUNX1;
c.270+1G>T, was noted in two index cases (F13.I and
F14.I). Candidate variations were present within ACTN1,
the 5’-UTR of ANKRD26, CYCS, FLI1, GFI1B, ITGB3,
GP1BA (heterozygous), MYH9, NBEAL2, RUNX1,
SLFN14, STIM1, TPM4 and TUBB1. All but six variants
were novel and not present within the variant databases
previously mentioned. Three variants, ANKRD26; c.-
126T>G in F2.I, MYH9; c.3493C>T (rs80338829) in F9.I
and RUNX1; c.530G>A in F19.I and F19.II have been pre-
viously associated with IT.1,19,20 The remaining three vari-
ants that have been previously observed occurred at fre-
quencies of <0.005 (0.05%) in available databases. One of
the databases scrutinized was that of the ExAC consor-
tium (http://exac.broadinstitute.org) which may include
data from individuals with low platelet counts who were
either undiagnosed or recruited through an unrelated
study (Table 2). Seven variants have previously been pub-
lished as part of two separate publications from the UK-
GAPP study group.8,15
Classification of the 28 variants occurring within the
known IT-related genes, following the interpretation
guidelines set out by Richards et al.,17 revealed  four vari-
ants to be “pathogenic”, 13 to be “likely pathogenic” and
11 to be of “uncertain significance”. Variants classified as
“pathogenic” were either already known to be a genetic
cause of IT; ANKRD26; c.-126T>G in F2.I and MYH9;
p.Arg1165Cys in F9.I, or were predicted to be loss-of-func-
tion variants in genes for which a loss of function is
known to cause disease; FLI1; p.Asn331Thr fs*4, in F4.I
and F4.II and RUNX1; pTrp79* in P12.I.
On average, less than one novel variant was expected to
be observed in the known IT-causing genes in which vari-
ants were observed. The number of variants occurring also
exceeds the expected number when extending the analy-
sis to cover variants with a mean allele frequency of <0.01.
Of the 37 index patients, four presented with two can-
didate variations in known disease-linked genes, which in
one case were present in the same gene. These were as
follows: F6.I (GFI1B; c.676+1G>A and STIM1;
p.Ala610Thr), F10.I (NBEAL2; (p.Leu459Arg fs*13 and
p.Asn2298Ser), F12.I (RUNX1; p.Trp79* and ITGB3
p.Arg117Trp) and F23.I (TPM4; p.Ala183Val and TUBB1;
p.Phe242Leu).
Of the 25 index cases with variants in known disease-
causing genes, nine were observed to have variants within
the RUNT1-related transcription factor gene; RUNX1.
One variant, RUNX1; p.Arg177Gln, observed in F19.I and
F19.II has been previously reported as a causative germline
mutation of a familial platelet disorder in two individuals
from the same pedigree.20 The variations consisted of five
missense variants, two splice-site variants and one non-
sense variant. One splice-site variation, c.270+1G>T, was
present within three affected individuals from two sepa-
rate families (F13 and F14). All variants, with the exception
of a missense substitution (p.D6N), lie within the genetic
region encoding the RUNT homology domain (RHD)
which mediates DNA binding and heterodimerization
with CBFβ (Figure 2).21 Platelets from the majority of these
patients (10/13) demonstrated a reduction in ATP secre-
tion and, in keeping with previous reports, several of these
patients displayed additional clinical features. Variations in
RUNX1 are associated with a propensity to myelodysplas-
tic syndrome and acute myeloid leukemia. To date, hema-
tologic malignancies have not been reported in any
patients; however, the brother of F16.1 did have a history
of acute myeloid leukemia but was unavailable for testing.
Potentially damaging variants in novel candidate genes
After scrutinizing individuals for variants within the
panel of 358 platelet-associated genes (Online
Supplementary Table S1), individuals without a variant in a
previously IT-associated gene were analyzed for variants
in novel genes. WES analysis revealed potentially damag-
ing candidate variants in three families with currently
unknown genetic etiology (Table 3). All candidate variants
are novel (excluding a previously annotated variant in
MKL1; p.Val575Met, which occurs at a frequency of
0.007718 within the ExAC consortium), segregate with
the disease status and have been confirmed by Sanger
sequencing.  
Variants within ANKRD18A, GNE and FRMPD1 in two
related individuals from consanguineous relationships
WES analysis of two related patients (F35.I and F35.II) of
South Asian ethnicity was approached differently to that
of other patients in this study. Both patients displayed a
similarly severe clinical phenotype with a significant
reduction in circulating platelets (15x109/L). Platelet func-
tion testing revealed a reduction in P-selectin (CD62P)
expression upon stimulation and variable fluorescent fib-
rinogen binding which was consistent across both affected
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individuals. The patients were cousins born from consan-
guineous relationships within a single consanguineous
kindred so the analysis was focused on identification of a
shared homozygous variant due to the recessive segrega-
tion of disease. Three variants occurring within
ANKRD18A; p.Glu799del, GNE; p.Gly447Arg and
FRMPD1; p.Ala509Val were present in both affected indi-
viduals and within a tightly linked region of homozygosi-
ty on chromosome 9p. The variations within ANKRD18A
and GNE were novel according to the previously men-
tioned databases whereas the variant in FRMPD1 has been
observed at a frequency of 0.0003708 including 39 times
within the South Asian population (rs571037699). There is
no ClinVar entry for this variant and all three variants are
classified as variants of “uncertain significance”. 
One missense variant in the recently proposed
inherited thrombocytopenia-linked gene, MKL1
One individual was shown to harbor a rare (frequency
<0.01) missense variant within the Megakaryoblastic
Leukaemia (translocation) 1 gene; MKL1.  The variant was
the only variant occurring within a gene of hemostatic rel-
evance within 109 significant novel variants. The variant;
MKL1; c.1723G>A, p.Val575Met present in patient F37.I
has been noted previously at a frequency of 0.0007718
(allele count of 6/7774 in the ExAC consortium). The
patient has a mild reduction in platelet count (130x109/L)
and no secondary qualitative defects in platelet function
were  observed. The variant is classified as of “unknown
significance”.
Novel missense candidate variants in PADI2 and TTF2
Three affected individuals and four unaffected related
individuals of a large kindred were recruited to the study.
Mild thrombocytopenia was observed within the family
with platelet counts ranging from 80x109/L to 186x109/L in
the three affected individuals. All three affected individu-
als presented with a normal platelet size (7.9-8.6 fL) and a
mild reduction in secretion was observed in F30.I and
F30.III but not in F30.II. All affected individuals shared a
similar bleeding phenotype, suffering from spontaneous
epistaxis, excessive bruising and prolonged bleeding from
minor wounds. WES analysis revealed 14 novel or rare
(frequency <0.01) variants shared between the three
affected individuals. Sanger sequencing of all 14 variants in
four unaffected related individuals narrowed down candi-
B. Johnson et al.
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Table 1. Platelet and bleeding phenotypes of 55 patients recruited to the UK-GAPP study.
Family Patient Platelet count MPV (fL) IPF (%) Secondary defect Bleeding phenotype
(x109/L)
1 I 73 9.6 Yes (Fibrinogen) Cutaneous bruising/bleeding, menorrhagia
2 I 50 8.6 No Cutaneous bruising
3 I 80 10.3 Yes (Cyclooxygenase) Cutaneous bruising, menorrhagia
II 50 12 Yes (Cyclooxygenase) Cutaneous bruising, epistaxis, purpura
III 98 10.5 3.2 N/A Cutaneous bruising, epistaxis, purpura
4 I 142 11.8+ Yes (Secretion and Gi) Oral cavity bleeding, epistaxis, menorrhagia
II 157 11.4+ Yes (Secretion) Cutaneous bruising, oral cavity bleeding
5 I 92 8.8 Yes (Secretion) Cutaneous bruising, epistaxis, bleeding into joints
II 100 8.6 Yes (Secretion) Cutaneous bruising, life-threatening bleeding following surgery
6 I 110 Yes (Secretion) Cutaneous bruising, excessive bleeding following surgery
II 100 8.9 Yes (Secretion) Cutaneous bruising, epistaxis
7 I 50 10.4 Yes (Secretion) Cutaneous bruising, menorrhagia
8 I 70 10.7+ No Cutaneous bruising, menorrhagia, post-partum hemorrhage
II 70 10.1 No Cutaneous bruising, epistaxis, hematuria, menorrhagia, 
post-partum hemorrhage
9 I 35 11.4+ No Epistaxis, cutaneous bruising.
10 I 55 N/A Cutaneous bruising, epistaxis
11 I 62 Yes (Secretion) Cutaneous bruising
II N/A Yes (Secretion) Cutaneous bruising, epistaxis
III 146 Yes (Secretion) Cutaneous bruising, epistaxis, menorrhagia
12 I 100 8 Yes (Secretion) Excessive cutaneous bleeding
13 I 163 9.1 No Cutaneous bruising, epistaxis, hematoma
II 45 11.9+ Yes (GPVI) Cutaneous bruising, epistaxis
14 I 139 8 Yes (Secretion) Epistaxis, hematoma
15 I 90 7.6- Yes (Secretion) Cutaneous bruising, petechiae
16 I 130 7.1- Yes (Secretion and Gi) Cutaneous bruising, epistaxis, oral cavity bleeding
II 70 7.5- Yes (Secretion and Gi) Cutaneous bruising, epistaxis, oral cavity bleeding
17 I N/A N/A N/A Excessive bruising/bleeding
18 I 110 8.1 Yes (Secretion) Cutaneous bruising/bleeding, petechiae, hematoma
continued on the next page
dates to only two missense variants; PADI2 (p.Lys499Arg)
and TTF2 (p.His1089Asp). Both variants segregate with
disease, not being present in the unaffected individuals.
Both variants have been observed previously at a low fre-
quency (<0.01) within the EXaC database (Table 3) and are
currently classified as being of “uncertain significance”.
Discussion
Here we present the first, large-scale application of WES
analysis to patients with inherited bleeding diatheses pre-
senting with thrombocytopenia of unknown etiology. 
Platelet counts and phenotypic presentations varied con-
siderably among the patients studied, which is consistent
with the variability observed in the spectrum of IT.
However, the majority of patients (73%) were noted to
have a secondary qualitative defect in platelet function
which may explain the disproportionate bleeding when
compared to the patients’ platelet counts. A lack of consis-
tency was noted in families 13 and 30, which apparently
included affected individuals both with and without
defects in platelet function. Clinical complications are
shared among the affected family members so this most
likely represents limitations in the sensitivity of platelet
function testing or intra-familial variability. 
Overall, when considering pathogenicity WES analysis
positively predicted pathogenicity in 46% of index cases
(17/37) (results classified as “pathogenic” or “likely patho-
genic” in a gene consistent with the patients’ phenotype
and zygosity consistent with expected inheritance).
Twenty-two percent of the index cases (8/37) had uncer-
tain/possible pathogenicity (results classified as being of
“uncertain significance” in known IT-causing genes). The
remaining 32% of index cases (12/37) had a negative pre-
diction of pathogenicity (no convincing variants identified
in known IT-causing genes). WES is not without its limita-
tions and, as with any genetic analysis, all variants must
be functionally confirmed as deleterious to the coded pro-
tein. However, our positive variant discovery rate is com-
parable to or exceeds the rates in previous large-scale WES
clinical multicenter studies of Mendelian disorders.22,23
Focusing our genetic analysis on patients with unknown
etiology of disease with minor prior genetic testing has
produced a spectrum of variants different from that from
previous, large-scale, targeted genetic studies of IT.
Patients were recruited to the study with clinically diag-
nosed bleeding disorders of unknown etiology. One
Whole exome sequencing in inherited thrombocytopenia
haematologica | 2016; 101(10) 1175
19 I 100 9 No Cutaneous bruising/bleeding
II 100 9.2 No Cutaneous bruising/bleeding
20 I 89 13+ 17.5 Yes (Secretion and Gi) Cutaneous bruising
21 I 63 11.9 19.1 Yes (Secretion) Cutaneous bruising, epistaxis, hematoma
II 83 11.9 24.3 Yes (Secretion) Cutaneous bruising, epistaxis, hematoma
22 I 74 11.2 Yes (Secretion and Gi) Cutaneous bruising/bleeding, hematuria
II 62 12.7+ 20.8 Yes (Secretion and Gi) Cutaneous bruising/bleeding, menorrhagia, post-partum hemorrhage,
hematoma
III 109 11 Yes (Secretion) Cutaneous bruising, hematoma, menorrhagia
23 I 119 11.1 Yes (Secretion) Cutaneous bruising/bleeding
24 I 104 9.6 No Menorrhagia, post-partum hemorrhage
II 133 8.6 No Epistaxis
25 I 11 13.4+ Yes (Secretion and Gi) Cutaneous bruising
26 I 43 14+ No Cutaneous bruising, menorrhagia, oral cavity bleeding
27 I 100 10.3 Yes (Secretion) Cutaneous bruising/bleeding, epistaxis, oral cavity bleeding
28 I 25 8.5 Yes (Secretion) Cutaneous bruising
29 I 15 9.4 Yes (Secretion) Hematomas
30 I 137 7.9 Yes (Secretion) Cutaneous bruising, epistaxis, menorrhagia
II 186 8.6 No Cutaneous bruising, menorrhagia, hematuria
III 80 8.2 Yes (Secretion) Cutaneous bruising
31 I 20 9.7 N/A Cutaneous bruising, epistaxis, oral cavity bleeding
32 I 15 9.5 20.2 No Cutaneous bruising
33 I 66 9.9 1.8 Yes (Secretion) Cutaneous bleeding
34 I 93 14.4+ 20.5 Yes (Secretion) Cutaneous bleeding, epistaxis
35 I 15 10.4 87 Yes (Secretion and other) Cutaneous bruising, epistaxis, hematomas
II 14 15+ 83 Yes (Secretion and other) Cutaneous bleeding
36 I 104 13.3+ 17 No Menorrhagia
37 I 130 9.7 No Cutaneous bruising, epistaxis, menorrhagia
Average platelet count = 85x109/L (normal range 147-327x109/L, n=40). Average mean platelet volume (MPV) = 10 fL (normal range 7.8-12.69 fL, n=40). Immature platelet fraction (IPF)
was available for 11 patients and varied between 1.8-87% (normal range 1.3-10.8%, n=40). Patients with an observed macro and micro thrombocytopenia are denoted by a + and -, respec-
tively, following their most recent analyzed MPV.  Secondary qualitative defects are abbreviated to the following; (Gi) - reduction in response upon ADP stimulation indicating a possible defect
in the Gi pathway, (GPVI) – reduction in surface GPVI quantity. Each individual bleeding diathesis is summarized under bleeding phenotype.
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caveat about this approach is the possible exclusion of
individuals with known Bernard-Soulier syndrome or
MYH9-related disorders as these two forms of IT are rou-
tinely tested for in many hematology centers in the UK.
However, three index cases with variants in either GP1BA
or MYH9 were noted in our analysis; these patients had
atypical presentations of Bernard-Soulier syndrome or
MYH9-related disorder and were, therefore, potentially
falsely-negatively reported cases. The individuals with
variants within GP1BA and MYH9 showed a slight
increase in mean platelet volume; however, this was not at
the magnitude of giant platelets normally attributed to this
group of disorders and only patient F9.I showed any sec-
ondary syndromic symptoms with the individual suffer-
ing from congenital cataracts.
One attribute of excluding patients with known variants
in GP1BA, GP1BB, MYH9 and potentially GP9 was the
discovery of a relatively large percentage of individuals
analyzed (24% of index cases) with variants in RUNX1 as
a primary likely cause of disease. With the exception of
one predicted loss-of-function variant, the variants present
within RUNX1 are currently classified as either “likely
pathogenic” or of “uncertain significance” and need func-
tional confirmation to be considered the cause of disease.
However, the presence of these variants in a large number
of individuals with an often shared secondary functional
defect in secretion does suggest that the prevalence of
RUNX1 variants may be higher than previously thought.
This raises the issue of whether they should be considered
as clinically significant as Bernard-Soulier syndrome and
MYH9-related disorders and be searched for in a primary
genetic screening at the initial diagnosis of IT. 
An advantage of using WES is the possibility of finding
candidate variations in novel genes in subjects who do not
possess variants in known IT-causing genes. The determi-
nation of whether these candidate variants are in fact
pathogenic relies on functional confirmation of the delete-
rious effect of the variant. However, WES analysis, espe-
cially with combined segregation analysis by Sanger
sequencing in extensive kindreds, can provide indications
as to which variants may be of scientific and clinical rele-
vance. This strategy has recently been utilized in the dis-
covery of novel candidate variations in SLFN14 initially as
part of the GAPP study.15,24
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Table 2. Results of whole exome sequencing analysis of 55 patients with inherited thrombocytopenia showing variants in known thrombocytopenia-caus-
ing genes. 68% of individuals have a predicted genetic etiology in a previously IT-associated gene. When a variant has been previously observed it is
annotated in the prevalence column with the database in which it is included. The ACMG consensus guideline results are also displayed in the final
classification column.17
Family Patient Gene(s) Genomic variation Protein effect Variation type Prevalence Classification
1 I ACTN1 c.2647G>C p.Gly883Arg Missense Novel Likely pathogenic
2 I ANKRD26 c.-126T>G 5'-UTR variation Known Pathogenic
3 I CYCS c.155C>T p.Ala52Val Missense Novel Likely pathogenic
II CYCS c.155C>T p.Ala52Val Missense Novel
III CYCS c.155C>T p.Ala52Val Missense Novel
4 I FLI1 c.992_995del p.Asn331Thr fs*4 Frameshift deletion Novel Pathogenic
II FLI1 c.992_995del p.Asn331Thr fs*4 Frameshift deletion Novel
5 I FLI1 c.1028A>G p.Tyr343Cys Missense Novel Likely pathogenic
II FLI1 c.1028A>G p.Tyr343Cys Missense Novel
6 I GFI1B c.814+1G>A Splicing Novel Likely pathogenic
STIM1 c.1828G>A p.Ala610Thr Missense 0.00019 (1k) Uncertain significance
II GFI1B c.814+1G>A Splicing Novel Likely pathogenic
STIM1 c.1828G>A p.Ala610Thr Missense 0.00019 (1k) Uncertain significance
7 I GP1BA c.1761A>C p.Gln587His Missense 0.00043 (EXaC) (rs570515282) Uncertain significance
8 I GP1BA c.413G>T p.Gly138Val Missense Novel Likely pathogenic
II GP1BA c.413G>T p.Gly138Val Missense Novel
9 I MYH9 c.3493C>T p.Arg1165Cys Missense Known (rs80338829) Pathogenic
10 I NBEAL2 c.1376delT p.Leu459Arg fs*13 Frameshift deletion Novel Likely pathogenic
NBEAL2 c.6893A>G p.Asn2298Ser Missense Novel Likely pathogenic
11 I RUNX1 c.16G>A p.Asp6Asn Missense Novel Likely pathogenic
II RUNX1 c.16G>A p.Asp6Asn Missense Novel
III RUNX1 c.16G>A p.Asp6Asn Missense Novel
12 I RUNX1 c.236G>A p.Trp79* Nonsense Novel Pathogenic
ITGB3 c.349C>T p.Arg117Trp Missense Novel Uncertain significance
13 I RUNX1 c.270+1G>T Splicing Novel Likely pathogenic
II RUNX1 c.270+1G>T Splicing Novel
14 I RUNX1 c.270+1G>T Splicing Novel
15 I RUNX1 c.322G>A p.Gly108Ser Missense Novel Uncertain significance
16 I RUNX1 c.427+1G>T Splicing Novel Likely pathogenic
II RUNX1 c.427+1G>T Splicing Novel
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Family 35 is an interesting case of two affected related
individuals born from consanguineous relationships. The
molecular function of ANKRD18A is currently unknown,
while FRMPD1 regulates the subcellular localization of
activator of G-protein signaling 3 (AGS3).25 Both genes are
expressed weakly in hematopoietic cells. However, GNE,
coding for an enzyme in the sialic acid biosynthetic path-
way, is expressed in all cells of the hematopoietic lineage.
There are currently 88 registered mutations in GNE in the
Human Genome Mutation Database
(www.hgmd.cf.ac.uk). Mutations are known to be the
genetic cause of sialuria (OMIM269921) and hereditary
inclusion body myopathy (OMIM600737).26,27 Recently,
two separate groups have reported patients with com-
pound heterozygous variations in GNE, causing GNE-
related myopathy with congenital thrombocytopenia.28,29
The platelet counts of the four reported affected individu-
als were below 45x109/L; platelet volume measurements
were not recorded. None of the patients displayed signs of
myopathy until mid-adolescence/early adulthood; F35.I
and F35.II are currently aged 10 and 6, respectively.
Without functional characterization of the effects of each
variation, we cannot definitively conclude the genetic eti-
ology of these two individuals’ severe thrombocytopenia.
However, WES analysis has allowed us to focus our efforts
on three potentially pathogenic variants in novel genes.
MKL1 was initially included in our panel of 358 genes
for post-WES analysis due to its role in megakaryocyte
maturation elucidated via its binding partner, serum
response factor (SRF).30-32 Recently, the first case of a
homozygous mutation in MKL1 in a patient with severe
immunodeficiency and no hematologic malignancies was
reported.33 One interesting phenotypic presentation of the
affected individual was an intermittent mild thrombocy-
topenia with low platelet counts in whole blood of
between 50x109/L and 150x109/L. Here we present a novel
variant within MKL1, at a highly conserved genetic site.
The missense variant observed in F37.I represents the only
variant to occur in a gene with previous hematologic
implications. One further variant in MKL1 was observed
in addition to a “likely pathogenic” frameshift causing
insertion within TUBB1 in patient F25.I. Due to the pre-
dicted loss of function of the frameshift causing the
TUBB1 variant it is unlikely that the variant with MKL1 is
additive to the phenotype of patient F25.I. However, the
variant of uncertain significance in patient F37.I is an inter-
esting candidate to take forward for functional studies.
WES and segregation determination using Sanger
sequencing revealed candidate variants in PADI2 and
TTF2 that segregate with disease in F30.I, F30.II and
F30.III. The phenotypic presentations vary between the
patients but clinical presentations are consistent, which
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17 I RUNX1 c.505A>G p.Thr169Ala Missense Novel Uncertain significance
18 I RUNX1 c.512A>T p.Asp171Val Missense Novel Uncertain significance
19 I RUNX1 c.530G>A p.Arg177Gln Missense Known Likely pathogenic
II RUNX1 c.530G>A p.Arg177Gln Missense Known
20 I SLFN14 c.652A>G p.Lys218Glu Missense Novel Uncertain significance
21 I SLFN14 c.657A>T p.Lys219Asn Missense Novel Uncertain significance
II SLFN14 c.657A>T p.Lys219Asn Missense Novel
22 I SLFN14 c.659T>A p.Val220Asp Missense Novel Likely pathogenic
II SLFN14 c.659T>A p.Val220Asp Missense Novel
III SLFN14 c.659T>A p.Val220Asp Missense Novel
23 I TPM4 c.548C>T p.Ala183Val Missense Novel Uncertain significance
TUBB1 c.726C>G p.Phe242Leu Missense Novel Uncertain significance
24 I TUBB1 c.721C>T p.Arg241Trp Missense 0.0001071 (ExAC)(rs368923302) Uncertain significance
II TUBB1 c.721C>T p.Arg241Trp Missense 0.0001071 (ExAC)(rs368923302)
25 I TUBB1 c.1080_1081insG p.Leu361Ala fs*19 Frameshift insertion Novel Likely pathogenic
26 I Unknown
27 I Unknown
28 I Unknown
29 I Unknown
30 I Unknown
II Unknown
III Unknown
31 I Unknown
32 I Unknown
33 I Unknown
34 I Unknown
35 I Unknown
II Unknown
36 I Unknown
37 I Unknown
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may reflect limitations in the sensitivity of platelet func-
tion testing. Neither gene has previously been implicated
in hematologic abnormalities: mutations in PADI2 have
been associated with schizophrenia, breast cancer and
rheumatoid arthritis, while mutations in TTF2 have been
associated with thyroid dysgenesis.34-37 WES analysis has
therefore provided us with the first steps for determining
the impact of these two variants of uncertain significance
and whether they have the propensity to be disease caus-
ing.
In summary, we show that WES can be applied to iden-
tify the underlying genetic cause in known IT-causing
genes for patients with thrombocytopenia and unclear dis-
ease etiology. We show similar positive detection rates
when compared to prior targeted studies and, with the
addition of complementary functional studies, show an
improved detection rate when compared to WES analysis
of other developmental disorders. We also suggest the
applicability of WES in providing preliminary insight into
novel genes and their potential mechanism of action
through candidate variations of unknown significance.
This approach provides a foundation to enhance our cur-
rent knowledge on megakaryopoiesis, platelet function
and platelet senescence/death through subsequent func-
tional studies. 
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Table 3. Potentially damaging variants in novel candidate genes.
FamilyGene Variant Protein Prevalence PhyloP PhastCons Mutation SIFT Provean PolyPhen-2 ACMG Classification
effect taster
30 PADI2 c.1496A>G p.Lys499Arg 0.000008681 1.647 1 Diseas-e Tolerated Neutral Benign PM  Uncertain
causing (segregation) significance
TTF2 c.3265C>G p.His1089Asp 1.65E-05 5.131 1 Disease- Damaging Deleterious Damaging PM Uncertain
causing (segregation) , PP3 significance
35 ANKRD18A c.2395_2397delhom p.Glu799delhom Novel 0.772 0.965 Polymorphism NA Deleterious NA PM2,  Uncertain
PP (segregation), PM6 significance
GNE c.1339G>Ahom p.Gly447Arghom Novel 5.343 1 Disease- Damaging Neutral Damaging PM2, Uncertain
causing PP (segregation), PM6 sgnificance
FRMPD1 c.1526C>Thom p.Ala509Valhom 0.0003708 -1.459 0 Polymorphism Tolerated Neutral Benign PP (segregation), Uncertain
PM6 significance
37 MKL1 c.1723G>A p.Val575Met 0.0007718 3.358 1 Disease- Damaging Neutral Damaging Uncertain
causing significance
When a variant has been previously observed it is annotated in the prevalence column with the database in which it is included. PhyloP scores vary between -14 and +6 and measure conservation at each
individual base, sites predicted to be conserved are assigned a positive score, fast evolving sites are assigned a negative score. Mutationtaster uses a Bayes classifier to predict the effect of a mutation. SIFT
damaging prediction score= <0.05. Provean deleterious score = <-2.5. PolyPhen-2 predictions are appraised qualitatively as benign or damaging.  The ACMG consensus guidelines, including supporting evi-
dence, are also shown.
Figure 2. Spatial amino acid locations of
all thrombocytopenia-causing variants
present within RUNT transcription factor
1 (RUNX1) (RefSeq NP_001001890).
Previously disease-causing variants found
the HGMD (www.hgmd.cf.ac.uk) and
ClinVar (www.ncbi.nlm.nih.gov/clinvar/)
databases are denoted above. The eight
variants found within RUNX1 in the GAPP
cohort of 54 patients who have under-
gone whole exome sequencing are denot-
ed below and the effect on the protein or
predicted splice-site is shown.
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